www.finanznachrichten.de · · DE
68737055 novartis pharma ag novartis delpacibart braxlosiran del brax phase i ii study in facioscapulohumeral muscular dystrophy fshd meets primary biomar 399
News Analysis — AI Analysis
Original analysis generated by News Analysis. This is our own commentary on the story, not the publisher's article text.
Novartis announced that the biomarker cohort data from its FORTITUDE Phase I/II study showed that del-brax met both primary and key secondary endpoints. These results, which indicated reductions in KHDC1L and creatine kinase levels, suggest strong target engagement and potential muscle protection for patients with facioscapulohumeral muscular dystrophy (FSHD). Novartis plans to use this data when engaging global regulatory authorities as it advances del-brax toward a Phase III study.
Key points
- The FORTITUDE biomarker cohort data demonstrated that the investigational drug, del-brax, met its primary and key secondary endpoints.
- Reductions in KHDC1L and creatine kinase levels suggest both effective target engagement and potential reduction of muscle damage in FSHD patients.
- Del-brax is an Antibody Oligonucleotide Conjugate (AOC) designed to address the root cause of FSHD by suppressing DUX4 expression.
- The drug has received Orphan Drug and Fast Track designations from the FDA and EMA, and is currently in Phase III development.
- Novartis' expanded neuromuscular pipeline includes del-desiran for myotonic dystrophy type 1 (DM1) and del-zota for Duchenne muscular dystrophy (DMD).
Claims assessed
- VerifiableThe biomarker cohort of the FORTITUDE Phase I/II study showed reductions in KHDC1L and creatine kinase levels, indicating strong target engagement and muscle protection.
- VerifiableDel-brax is an investigational agent that has received Orphan Drug and Fast Track designations from the FDA and EMA.
- VerifiableThe Phase I/II study (NCT05747924) evaluated del-brax in 90 patients with FSHD using a randomized, double-blind, placebo-controlled design.
Missing context
The article does not provide the magnitude or statistical significance (e.g., p-values) of the observed reductions in KHDC1L and creatine kinase, which are critical details for assessing clinical impact. It also lacks specific timelines regarding when Novartis expects to complete Phase III trials.
Topic context
The full article is on the original publisher site.
Related stories
bigpara.hurriyet.com.tr
yatirimci tcmb ve ecb faiz kararlarina odaklandi ID
kurier.at
Iran Krieg Israel USA Angriff Nahostkrieg Livebericht 11 Juni
thehindubusinessline.com
It Drags D Street Lower as Investors Turn Cautious on West Asia Tensions US Inflation Data Oil Spike
economictimes.indiatimes.com
World Markets Walk a Tightrope Between AI Stocks and Oil Shocks
miragenews.com